ZFPM2

Across TCGA pan-cancer cohorts, ZFPM2 Mutation is linked to patient survival in 14 of 34 cancer types, making it a survival-associated ZFPM2 data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher ZFPM2 Mutation is associated with better overall survival. In most high-consensus cancer types, elevated ZFPM2 expression acts as an unfavorable survival marker, although some lineages such as STAD and ESCA show a favorable association.

STAD, ACC, and BLCA are the cancer types where ZFPM2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	1.000	0.388	.004	23	view →
ACC	OS	Median	All	0.158	0.640	.002	21	view →
BLCA	DFS	Median	III,IV	0.114	0.577	<.001	21	view →
LUSC	OS	Median	II,III,IV	0.309	0.630	<.001	18	view →
ESCA	DFS	Median	II,III,IV	0.847	0.284	.031	11	view →
UCEC	DFS	Median	II,III,IV	0.882	0.433	.022	10	view →
READ	OS	Median	II,III,IV	0.638	0.914	.026	9	view →
TGCT	DFS	Median	All	0.094	0.801	.008	6	view →
PRAD	DFS	Median	All	0.839	0.934	.031	6	view →
HNSC	DFS	Median	All	0.189	0.626	.043	3	view →
COAD	OS	Median	III,IV	0.140	0.696	.027	3	view →
LIHC	OS	Median	All	0.221	0.679	.002	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 14 lineages.

ZFPM2–STAD (OS)

Open the STAD breakdown →